Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Paul S. Wissel, MD

Paul S. Wissel, MD Provider Not Employed by Penn Medicine

Adjunct Professor of Medicine

Dr. Wissel is a private practice physician who is not employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

  • Gastrointestinal Cancer Program

Board Certification:

  • Internal Medicine, 1983
  • Medical Oncology, 2012

Clinical Expertise:

  • Abdominal Chemotherapy
  • Anal Cancer
  • Anorectal Cancer
  • Appendix Cancer
  • Bile Duct Cancer (Cholangiocarcinoma)
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Carcinoid of the Stomach
  • Carcinoid Tumor of Pancreas
  • Carcinoid Tumors
  • Colon Cancer Chemotherapy
  • Cystadenoma of Pancreas
  • Esophageal Cancer
  • Gallbladder Cancer
  • Gallbladder Mass
  • Gastrointestinal Stromal Tumors (GIST)
  • Hepatobiliary Malignancies
  • Hereditary Colon Cancer
  • Hereditary Nonpolyposis Colorectal Cancer
  • Immunotherapy
  • Insulinoma
  • Malignant Neoplasm of Pancreatic Duct
  • Malignant Tumor of Extrahepatic Bile Duct
  • Pseudomyxoma Peritonei
  • Small Bowel Cancer
  • Squamous Cell Carcinoma of the Esophagus
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Columbia University
Residency: Ohio State University Hospital
Residency: University of Cincinnati Medical Center
Fellowship: Memorial Sloan-Kettering Cancer Center

Memberships

American College of Physicians, National American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Wissel is a private practice physician who is not employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.: A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Cancer Chemother Pharmacol. 81 (3): 609-614,2018.

Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H.: Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies Cancer 122 (12): 1871-179,2016.

Stéphane Temam, Anil D'Cruz, Minish Mahendra Jain, Ida D'Onofrio, Georgy M. Manikhas, Geza Horvai, Yan Sun, Stefan Dietzsch, Pavol Dubinsky, Petra Holeckova, Hisham Mehanna, Iman El-Hariry, Natalie Franklin, Nigel Biswas-Baldwin, Philippe Legenne, Paul Stephen Wissel, Thelma Netherway, Sergio Santillana, Jean Bourhis: Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). Kevin J. Harrington, Journal of Clinical Oncology 23 (6005): 2014.

Tudor-Eliade Ciuleanu, Igor Bazin, Dan Lungulescu, Lucian Miron, Igor Bondarenko, Andrzej Deptala, Maribel Rodriguez-Torres, Bruce J. Giantonio, Weijing Sun, Norma Lynn Fox, Gursel Aktan, Paul Stephen Wissel, Jacki Egger, Meichun Ding, Rubana Kalyani Matthew Joseph Gribbin;: Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology 32 (4029): 2014.

Sohal D., Teitelbaum U., Uehara T., Mykulowycz K., Watt C.D., Damjanov N., Giantonio B., Carberry M., Wissel P., Jacobs-Small M., O'Dwyer P., Sun W., Sepulveda A.R., Sun W.: Mutational analysis of EGFR, KRAS and BRAF in advanced cholangiocarcinoma and association with clinical outcomes - An interim report of a phase II trial Ann Oncol. 24 (12): 3061-5,2013.

Rodryg Ramlau, Jacek Jassem, Zsolt Papai-Szekely, Pierre Chabot, Philippe Legenne, Jeremey Levin, Jadwiga Sherlock, Stephen R. Lane, John J Brennan, Tracey Sessa, Paul Stephen Wissel, Philip Bonomi: Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study Journal of Clinical Oncology 31 (2031): 2013.

Bojana Milojkovic Kerklaan, Martijn P. J. K. Lolkema, Lot A. Devriese, Emile E. Voest, A. Nol-Boekel, M. Mergui-Roelvink, Kristine Mykulowycz, Joseph E Stoebenau, Lei Fang, Philippe Legenne, Paul Stephen Wissel, Deborah A. Smith, Bruce J. Giantonio, Jan HM Schellens, Petronella Witteveen: Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors. Journal of Clinical Oncology 31 (2536): 2013.

Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Walter B. Roland, Rebecca L. Olin, Azra Raza, Aristotles Giagounidis, Oliver G. Ottmann, Aref Al-Kali, Elias J. Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, John Z. Zhu, Paul Wissel, and Hagop M. Kantarjian: Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease Blood 120 (677): 2012.

Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J.: Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncology 10 (6): 549-58,2009.

Fields AL, Keller A, Schwartzberg L, Bernard S, Kardinal C, Cohen A, Schulz J, Eisenberg P, Forster J, Wissel P.: Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. Journal of Clinical Oncology 27 (12): 1941-7,2009.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
3400 Civic Center Blvd

Philadelphia, Pa 19104
Phone: (215) 662-7606
Patient appointments: 800-789-7366 (PENN)

Related Links